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A critical need in understanding the biology of
prostate cancer is characterizing the molecular dif-
ferences between indolent and aggressive cases.
BecauseDNAmethylation can capture the regulatory
state of tumors, we analyzed differential methylation
patterns genome-wide among benign prostatic tis-
sue and low-grade and high-grade prostate cancer
and found extensive, focal hypermethylation regions
unique to high-grade disease. These hypermethyla-
tion regions occurred not only in the promoters of
genes but also in gene bodies and at intergenic
regions that are enriched for DNA-protein binding
sites. Integration with existing RNA-sequencing
(RNA-seq) and survival data revealed regions where
DNA methylation correlates with reduced gene
expression associated with poor outcome. Regions
specific to aggressive disease are proximal to genes
with distinct functions from regions shared by indo-
lent and aggressive disease. Our compendium of
methylation changes reveals crucial molecular dis-
tinctions between indolent and aggressive prostate
cancer.
INTRODUCTION
Prostate cancer remains the second most common cause of
cancer deaths in American men, with 220,800 estimated new
cases and 27,540 estimated deaths for 2015 (Siegel et al.,
2015). Accurately differentiating between indolent and aggres-
sive disease is of utmost importance to reduce overtreatment
so that men with indolent cancers are spared the morbidities
of radical therapy while those with potentially life-threatening
cancers will undergo treatment with curative intent. However,Cell Reptriggers for radical therapy still require refinement for the 14%
to 41% of low-risk patients who actually have more aggressive
disease (Cooperberg et al., 2011). Recently, a gene-expres-
sion-based assay using biopsy tissues has provided a genomi-
cally derived aggressiveness measure that clinicians can use in
conjunction with clinicopathologic risk factors for supporting
clinical decision-making (Klein et al., 2014). Still, knowledge
about the molecular and biological differences between indolent
and aggressive prostate cancer can be increased further, as
most genome-wide studies of copy-number variation, somatic
mutations, DNA methylation (Kim et al., 2011; Yu et al., 2013),
and gene expression have focused on tumor versus normal com-
parisons rather than stratifying by aggressiveness subtypes.
We sought to uncover molecular mechanisms behind aggres-
sive prostate cancer by comparing DNA methylation profiles
between benign prostate, indolent prostate cancer, and aggres-
sive prostate cancer. DNAmethylation is a compelling candidate
for involvement in prostate cancer aggressiveness due to the
comparatively low somatic mutation rate in prostate tumors
(Taylor et al., 2010) and the reported overexpression of DNA
methyltransferases in prostate cancer (Kobayashi et al., 2011).
Two alternative ways to divide prostate cancers into aggres-
siveness groups for research are by outcomes (recurrence
and/or prostate cancer specificmortality) or by histopathological
grading. We have elected to stratify by histology, because our
goal is to find molecular differences between these subtypes,
and outcomes can be confounded by stage at presentation
and case management decisions. Histologic Gleason scores
(6–10 used in practice) derived from radical prostatectomy
sections highly correlate with tumor aggressiveness when
considered in terms of biochemical recurrence, development
of metastatic disease, and mortality due to prostate cancer
(Albertsen et al., 1998; Epstein et al., 1996; Pan et al., 2000).
Moreover, studies have established that Gleason score 6 tumors
almost entirely lack the capacity to metastasize to lymph nodes,
as metastatic disease is nearly entirely confined to tumors
with Gleason scores 7 and above (Ross et al., 2012). To detectorts 13, 2135–2146, December 15, 2015 ª2015 The Authors 2135
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Figure 1. Detection of DMRs among Benign Prostate and Low-Grade and High-Grade Prostate Cancers
(A) Principal component analysis (PCA) based on the top five million most variable non-overlapping 50-bp windows in the genome as defined by the coefficient of
variation. Proportions of explained variance for each principal component are given in parentheses. The center of each cluster formed by the group assignments
has been plotted with a crosshair. Bootstrap false discovery rates (FDRs) for the Euclidean distance between cluster centers based on 100,000 iterations are
provided along the gray lines connecting the cluster centers. One outlier (sample ‘‘BA1’’) has been removed from this plot and the FDR calculations (see Fig-
ure S1A for plot and FDRs including ‘‘BA1’’).
(legend continued on next page)
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DNA methylation changes specific to either indolent or aggres-
sive cancers, we divided samples into three groups: benign
prostatic tissue, low-grade (indolent, Gleason score 6) prostate
cancer, and high-grade (aggressive, Gleason score 8–10) pros-
tate cancer. We used benign tissue from men who underwent
cystoprostatectomy for non-prostate pathology that did not
have any evidence of prostate cancer or pre-cancerous lesions,
because tumor-adjacent benign tissue from men with prostate
cancer is known to harbor DNA methylation changes associated
with prostate cancer (Mehrotra et al., 2008).
Of the patterns of differentially methylated regions (DMRs) we
detected, hypermethylation specific to high-grade (high grade
DMRs) and hypermethylation shared by low and high grades
(shared DMRs) were the strongest and most statistically robust.
High-gradeDMRsoccurredmore frequently at intergenic regions
and gene bodies than other genomic contexts. These DMRs,
including the intergenic, are enriched for putative functional ele-
ments (DNaseI hypersensitive sites, chromatin immunoprecipita-
tion sequencing (ChIP-seq) peaks, and enhancer-like chromatin
states). Several high-grade DMRs inversely correlate with the
expression of genes that associate with poorer outcomes in
meta-analysis. A network analysis of genes proximal to high-
gradeDMRs revealed distinct functional enrichments fromgenes
proximal to shared DMRs. These results provide valuable insight
into aggressive prostate cancer biology, and future work will
address the function of specific loci and the possibility of a
DNA-methylation-based diagnostic test distinguishing indolent
from aggressive cancers.
RESULTS
Dimensionality Reduction of Methylome-wide
Sequencing Data Separates Benign, Low-Grade, and
High-Grade Prostate Cancer Specimens
We performed MBD (methyl-CpG binding domain)-isolated
genome sequencing (MiGS) (Serre et al., 2010) on benign pros-
tatic tissue obtained from cystoprostatectomy specimens and
low-grade and high-grade prostate cancer specimens obtained
from radical prostatectomies (Table S1). A principal component
analysis (PCA) was performed to investigate whether variations
in DNA methylation genome-wide can distinguish among the
groups (Figures 1A and S1A). The first principal component
partly separates low-grade from high-grade cases, and benign
samples separate when considering the second and third prin-
cipal components with one outlier (excluded in Figure 1A and(B) Summary of DMRs for each possible pattern of hyper- and hypomethylation am
square in the ‘‘DNAMethylation Pattern’’ columns are hypermethylated with respe
state for two thirds or more of the samples in each group must be consistent. FD
(C) Heatmap of ‘‘frequent’’ DMRs reported in (B). Each row represents one DMR.
involved and square root transformed before plotting. The color scale was gener
Dark blue represents read values below this threshold, indicating an absence or tr
presence of methylated sequence.
(D) Differential methylation in the gene body of CD14, including two high-grade DM
50-bp window are plotted for each of the three groups (colors as in Figure 1A). R
with collapsed gene models for RefSeq genes, CpG islands, ENCODE DNaseI h
passed CpG sites assayed by the TCGA methylation microarray are shown.
(E) A shared DMR located in a cluster of PCDHG genes and over the transcriptio
is 0–42 reads.
Cell Repincluded in Figure S1A). Excluding the outlier, bootstrap false
discovery rates (FDRs) for the distances between group cen-
troids are below 10%: 3.2% for benign versus low grade, 7.0%
for benign versus high grade, and 3.2% for low grade versus
high grade. Although the samples are from a mixture of pa-
tients from European American and African American ancestry,
a MANOVA indicates that sample group significantly (p < 0.05)
associates with the first three principal components (p = 4.9 3
107), whereas ancestry (p = 0.16) and the interaction of ancestry
and group (p = 0.05) do not. In spite of some heterogeneity within
groups, the dimensionality reduction and clustering indicate that
the DNAmethylation sequencing data contain variability that can
distinguish these three groups.
Hypermethylation at Specific Genomic Regions
Distinguishes Indolent and Aggressive Prostate Cancer
Specimens
We identified all statistically significant quantitative differences in
read counts (at adjusted p value < 0.01) produced by MiGS in
regions R150 bp for all possible patterns of methylation differ-
ences among the three groups (Figure 1B; Table S2). The two
most robust patterns of DMRs were hypermethylation shared
by low and high grades (shared DMRs: 8,944 sites, ranging
from 150 bp to 3,450 bp, covering 2,972.4 kb in total) and hyper-
methylation specific to high grade (high-grade DMRs: 4,932
sites, ranging from 150 bp to 900 bp, covering 919.15 kb in total).
To establish significance of observing DMRs from each pattern,
we called DMRs in 1,000 bootstrap resamples of the group
assignments, and these two patterns had the lowest FDRs
(19.3% for shared DMRs and 22.2% for high-grade DMRs). We
also stratified DMRs into a ‘‘frequent’’ subset where the qualita-
tive methylation status of two-thirds of samples in each group
was in agreement (Figure 1C). In this subset, FDRs were even
lower for the high-grade (6.5%) and shared (4.9%) DMRs yet
remained high (17.9%) for the third most significant pattern
(hypomethylation specific to low grade).
At a p value cutoff of 0.001 (Figures S1B–S1D), FDRs for the
high-grade and shared DMRs are even lower (13% and 6%),
yet both patterns retain a substantial number of DMRs (1,712
and 4,018). One thousand bootstraps were sufficient to provide
stable estimates of the random populations, as a plot of permu-
tation numbers versus FDRs shows stabilization for all DMRs
(Figures S1E and S1F). We also used the DMR lists from these
bootstraps to compute FDRs for each observed DMR and found
that nearly all DMRs, regardless of pattern (all but 4 of 33,788),ong the three groups using a p value cutoff of 0.01. Groupsmarked with a filled
ct to groupswith white squares. In ‘‘frequent’’ DMRs, the predictedmethylation
Rs are a result of 1,000 bootstrap iterations.
Read values for the regions were normalized to the number of 50-bp windows
ated to inflect at the initial filtering threshold for presence of DNA methylation.
ace amounts of methylation. Dark red represents high read values, indicating a
Rs and one shared DMR. The normalized read counts (mean ± SEM) for each
ead counts for three select individual samples (y axis scale: 0–33 reads), along
ypersensitive sites (HSS), ENCODE ChIP-seq peaks, and locations of filtering-
n start site of PCDHGA11. y axis scale for select samples in the browser view
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Figure 2. Genomic Context and Putative Functional Element Relationships for High-Grade and Shared DMRs
(A) Proportion of DMRs that overlap with the genomic context categories of intergenic, promoter (1,000 bp to +500 bp of a transcription start site), exon, intron,
and 30 end (±1 kb from transcription stop sites). Categories were made mutually exclusive in cases of multiple overlaps by using the priority: promoter, 30 end,
exon, intron, intergenic.
(B andC) Proportion of high-grade (B) and shared (C) DMRs that overlapwith genomic feature sets of CpG island, CpG shore (±2 kb of islands), CpG shelf (±2 kb of
shores), ENCODE transcription factor binding sites (TFBS), and ENCODE DNaseI hypersensitive sites (DNaseI).
(legend continued on next page)
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had site-specific FDRs below 5% (Figure S1G). When consid-
ering fold change, differences were higher in the high-grade
(log2 high/benign of 2.00 and high/low of 1.61) and shared
(log2 high/benign of 2.79 and low/benign of 2.39) DMRs when
compared to others, particularly the patterns of hypomethylation
(Figure S1H). Thus, high-grade and shared DMRs were the most
statistically robust and quantitatively strong patterns, and we
focused our characterization on these two sets.
Here, we highlight examples of high-grade and shared DMRs
to illustrate the regional and contextual nature of these differ-
ences. The first example occurs in the gene body ofCD14, which
contains both high-grade DMRs and a shared DMR (Figure 1D).
The regional signal plots for two neighboring high-grade DMRs
reveal that high-grade samples have high methylation signals
compared to both low-grade (log2 high/low of 1.90 and 2.77)
and benign (log2 high/benign of 2.66 and 4.49) samples.
Notably, only the African American low-grade samples show hy-
permethylation at the shared DMR near the gene promoter, and
this DMR is 166 bp away from a SNP that is associated with
aggressive prostate cancer in African Americans (Mason et al.,
2010). This is interesting in light of prior research suggesting
that patients with African ancestry have a higher risk of aggres-
sive disease (Yamoah et al., 2015). The second example is a
shared DMR within the first exon of protocadherin gamma sub-
family A, 11 (PCDHGA11) (Figure 1E). Robust DNA methylation
is detected in both the low-grade and high-grade groups, but
not in the benign specimens (log2 high/benign of 2.54 and log2
low/benign of 2.54). This DMR is located in the gene bodies of
overlapping genes from the protocadherin family. Differential
DNA methylation in this region has been previously detected in
a chemical screen for initiating DNA methylation events in pros-
tate cancer (Severson et al., 2012). In summary, the high-grade
and shared DMR sets of focal differences in DNA methylation
robustly distinguish indolent and aggressive prostate cancers
from each other and from benign prostatic tissue in our cohort.
High-Grade DMRs Frequently Occur in Intergenic and
Gene Body Contexts in Addition to Gene Promoters
To begin understanding the potential functions of DMRs, we
examined the spatial relationship between DMRs and RefSeq
coding gene models (promoters, exons, introns, and gene 30
ends) by overlapping the DMR coordinates with annotated
genes (Figure 2A). The analysis revealed that DMRs are enriched
for promoters (17.5% of the shared DMRs and 8.7% of high-
grade DMRs versus 1.4% in the background set) and gene 30
ends (5.1% of the shared DMRs and 4.7% of high-grade
DMRs versus 1.6% in the background set). Notably, the pro-
moter context was more common for shared DMRs than for
high-grade DMRs (odds ratio [OR], 2.23; 95% confidence inter-
val [CI], 1.99–2.51). Both sets of DMRs also frequently occur in
intergenic contexts (36.0% of the shared DMRs and 31.6% of(D) Enrichment of high-grade DMRs for consensus DNA-protein binding sites bas
seq factor. The numerical values indicate the number of DMRs overlapping in
enrichment for this overlap. Enrichment is with respect to all regions covered by M
(E) Enrichment of DMRs for DNaseI hypersensitive sites, ChIP-seq, and nucleo
cancer cells and tissues (PEpi, prostate epithelial; PCa, prostate cancer).
(F) Proportion of DMRs that overlap with active enhancer annotations as compa
Cell Repthe high-grade DMRs). This enrichment of DMRs in regions
beyond gene promoters raises the possibility of varied functions
for DNA methylation in different genomic contexts in prostate
cancer, and these non-promoter functions may be especially
pervasive in high-grade cancers.
We next examined the DMRs with respect to putative func-
tional elements and CpG islands (Figures 2B and 2C) and
observed two striking features. First, the intergenic DMRs
appear highly enriched for DNaseI hypersensitivity sites (72%
of high-grade DMRs and 89% of the shared DMRs versus 25%
in the background set) and ChIP-seq peaks from the ENCODE
project (57% of high-grade DMRs and 78% of the shared
DMRs versus 17%% in the background set). Second, shared
DMRs were more commonly located over CpG islands and
shores than high-grade DMRs. These observations prompted
us to further investigate the overlap of DMRs with specific puta-
tive regulatory elements in more detail.
High-Grade and Shared DMRs Occur over Putative
Transcription Factor Binding Sites and Enhancers
We next explored if binding sites for any particular DNA-binding
proteins are enriched in the DMRs using reference data. An
enrichment analysis of high-grade and shared DMRs with
consensus ChIP-seq peaks from the ENCODE project revealed
a strong enrichment for enhancer of zeste 2 (EZH2) and retino-
blastoma binding protein 5 (RBBP5) in the intergenic context
(Figures 2D and S2A). EZH2 is recruited to chromatin via inter-
actions with nascent RNA, indicating transcriptional activity
(Davidovich et al., 2013; Kaneko et al., 2013). Potential for
binding of this factor in the intergenic DMRs suggests we
may have identified unannotated transcription units that could
impact phenotype. These sites may also be associated with
distal enhancer and repressor elements, which can produce reg-
ulatory RNAs (Wang et al., 2011). To complement the experimen-
tally derived transcription factor binding data, we also performed
a de novo motif analysis (Figure S2B). Notably, an EGR1-like
motif was found in high-grade DMRs, and a MAFB-like motif
was found in shared DMRs.
Analysis using the entirety of ENCODE data indicated the
potential for regulatory activity at the intergenic DMRs, but not
necessarily in prostate cells specifically. Therefore, we leveraged
datasets specific to prostate and prostate cancer cells to corrob-
orate the findings above. Consistently, high-grade and shared
DMRs across all genomic contexts are enriched for DNaseI hy-
persensitive sites and ChIP-seq peaks in prostate cancer cell
lines including Polycomb repressive complex 2 components
EZH2 and SUZ12 (Figure 2E). High-grade and shared DMRs
also overlap with nucleosome depleted regions (NDRs) that are
present in benign prostate cells and lost in PC3 prostate cancer
cells, which may represent enhancers decommissioned in carci-
nogenesis (Taberlay et al., 2014). Furthermore, non-promotered on ChIP-seq data from the ENCODE project. Each row represents a ChIP-
each context while the heatmap color represents the degree of statistical
iGS in the same genomic context. See also Figure S2A for the shared DMRs.
some depleted regions (NDRs) in previously published prostate and prostate
red to genomic background.
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Figure 3. Hypermethylation and Hypervariability in TCGA Array Sites at High-Grade and Shared DMRs
(A) Number and proportion of DMRs that contain one or more TCGA array site.
(B) Proportion of TCGA-assayed DMRs with statistically significant differential methylation with respect to adjacent normal tissue as compared to the array
background.
(C) Proportion of TCGA-assayed DMRs with statistically significant differential variance with respect to adjacent normal tissue as compared to the array
background.
(D) Beta values from TCGA DNA methylation microarray data for an array site located inside the high-grade DMR shown in Figure 1D.
(E) Beta values for a TCGA array site located inside the shared DMR shown in Figure 1E.
(F) Beta values for a TCGA array site located inside the high-grade DMR shown in Figure S3C.high-grade (OR, 5.6; 95% CI, 5.3–6.0) and shared (OR, 5.0;
95% CI, 4.8–5.3) DMRs overlap substantially with annotated en-
hancers in prostatic cells and tissues than expected of genomic
background (Figure 2F). Additionally, >70% of non-promoter
high-grade and shared DMRs are annotated as putative active
enhancers across cells and tissues. Taken together, the results
of the enrichment analyses raise many functional possibilities
for the DMRs and suggest that the impact of DMRs residing in
intergenic sequences may be just as strong as those proximal
to known genes.
High-Grade and Shared DMRs Overlap with
Differentially Methylated and Differentially Variable
Single-CpG Microarray Sites from TCGA
We sought to verify our DMRs by leveraging the DNAmethylation
microarray data from The Cancer Genome Atlas (TCGA) (Table
S3). However, this comparison is complicated by the fact that
the array only assays single CpG sites and covers less than
2% of CpG sites across the genome (Clark et al., 2012), while2140 Cell Reports 13, 2135–2146, December 15, 2015 ª2015 The Auour data from MiGS detects regions R150 bp and covered
80.7% of 50-bp windows genome-wide that contain three or
more CpG sites. Shared DMRs were covered by array sites
more frequently than high-grade DMRs, and 77% of our high-
grade DMRs were not able to be measured by TCGA (Figure 3A).
Focusing on DMRs that do contain array sites, 74.0% of shared
DMRs contain hypermethylation shared by low- and high-grade
TCGA samples, as stratified using the available clinical data (Fig-
ures 3B and S3B). A smaller percentage (8.9%, 101 DMRs) of
high-grade DMRs contained statistically significant TCGA high-
grade hypermethylation, and this proportion is greater than the
null expectation of 1.7% from the entire array (OR, 11.3; 95%
CI, 9.0–14.0) (Figures 3B and S3A). A small number of shared
DMRs had high-grade hypermethylation in TCGA, and a large
number of high-grade DMRs tested significant for shared hy-
permethylation in TCGA. Also, 4.1% of high-grade DMRs over-
lapped with differentially variable sites where variance was
uniquely elevated in high grade when compared to low grade
and the adjacent normal tissues (Figure 3C), suggesting thatthors
some high-grade DMRsmay concentrate in subtypes and not be
sufficient to test as statistically significant differences in means.
The array sites for the CD14 DMR and PCDHGA11 DMR show
significant differential hypermethylation (Figures 3D and 3E),
and an example of a site with differential variability occurs near
the gene EYA1 (Figures S3C and S3F). Because many of our
high-grade DMRs overlap with cancer-specific hypermethyla-
tion in TCGA, we surmise that the limited concordance of
total high-grade DMRs could stem from differences in sample
classification due to inter-observer variability in Gleason grade
assignments between our current study and TCGA. Such inter-
observer variability, while minimally affecting cancer versus
non-cancer categorization, is well known (McKenney et al.,
2011) and can contribute to discrepancies in the detection of
high-grade-specific DMRs. Regardless of exact histological as-
signments and purity in TCGA, large fractions of both high-grade
and shared DMRs overlap with differential methylation and dif-
ferential variance sites in TCGA.
High-Grade DMRs Correlate with Changes in mRNA
Expression that Associate with Poorer Survival in
Prostate Cancer Patients
Having established hypermethylation and hypervariability at
TCGA array sites within our DMRs, we leveraged TCGA’s
RNA-seq data to explore correlations with gene expression.
DMRs were divided into promoter and gene body with respect
to a reference-guided de novo transcriptome assembly (Pertea
et al., 2015) we performed on 537 TCGA RNA-seq samples
that also had DNA methylation microarray data. For each site
within a DMR, we computed Pearson’s correlation coefficients
between the site’s fractional methylation level (beta-value) and
the fragments per kilobase of transcript per million mapped
reads (FPKM) expression level of the overlapping gene. Against
a null expectation established by correlating each gene against
all quality control (QC)-passed 440,706 sites on the array, both
promoter and gene body show a large population of inverse cor-
relations, whereas gene bodies uniquely have a large population
of positive correlations (Figure 4A). Requiring an FDR of <5%and
a correlation magnitude of greater than 0.4, nine high-grade
genes and 75 shared genes had strong promoter correlations
with expression, while 26 high-grade genes and 147 shared
genes had strong gene body correlations (Tables 1 and S4).
For example, the high-grade DMR in the promoter of CCDC8
showed a strong negative correlation with gene expression (Fig-
ures 4B and 4C). In contrast, the high-grade DMR in the gene
body of HOXC4 showed a strong positive correlation with gene
expression (Figures 4D and 4E). These possibilities demonstrate
that DNAmethylation may have different functions depending on
the genomic context and that correlations of DNA methylation to
gene expression are not limited to gene promoters and inverse
relationships. Indeed, the potential activating effect of gene
body methylation has been reported by others (Jjingo et al.,
2012), and effects of gene body DMRs on gene expression
may be linked to the presence of gene body enhancers (Agirre
et al., 2015).
Next, we evaluated whether the genes correlated with DMRs
have implications for prostate cancer aggressiveness by exam-
ining the survival z-scores generated by the PRECOG meta-Cell Repanalysis of prostate cancer outcomes (Gentles et al., 2015).
The majority of high-grade genes with strong and significant
inverse correlations between methylation and expression also
showed a negative PRECOG z-score, which indicates that
decreased expression is associated with poorer outcomes (Fig-
ure 4F). For example, reduced expression of myosin light chain
kinase (MYLK) is associated with poorer outcomes (PRECOG
z-score 3.2) and has a gene body DMR (Figure 4G; log2 high/
low of 1.04) inversely correlating with gene expression (Fig-
ure 4H; r = 0.54, FDR = 0.19%).
Known Prostate Cancer Genes Are Proximal to
High-Grade and Shared DMRs
While our analysis of putative functional elements and integra-
tion with RNA-seq data provided a view of the DMRs from a
sequence context perspective, we have also analyzed how
DMRs relate to known genes to provide a cellular context. 249
genes overlapping with 376 high-grade DMRs have strong links
to either prostate cancer or cancers in general based on a gene
panel assembled from the literature (Table S5). These genes
span multiple pathways, including androgen receptor (AR)
signaling (NCOR2, SRD5A2), DNA damage response (PRKDC),
and growth factor receptors (FGFR1, FGFR2, IGF1R, EGFR).
Some genes have specific and established links to aggressive-
ness, such as protein kinase, DNA-activated, catalytic polypep-
tide (PRKDC) that is involved with induction of metastasis and
independently predicts for recurrence and poor survival (Good-
win et al., 2015). The gene SRD5A2 codes for the enzyme ste-
roid-5-alpha-reductase, alpha polypeptide 2, which has reduced
expression in aggressive prostate cancers (Mitsiades et al.,
2012). SRD5A2 is also part of a gene expression prognostic
test with predictive power for aggressive prostate cancer (Klein
et al., 2014) and has the third lowest prostate cancer z-score
(8.7) in PRECOG. For comparison, the shared DMRs overlap
with 434 panel genes across 786 DMRs. There are 134 genes
targeted by both types of DMRs, including HOTAIR, ESR1,
FOXF2, and ZBTB16. This result suggests that both types of
DMRs target known genes in major prostate cancer pathways
and that high-grade DMRs mark aggressiveness-related genes.
Genes near High-Grade DMRs Possess Distinct
Functions from Those near Shared DMRs
We realized that the gene panel assembled above could not cap-
ture all the DMR-associated genes; thus, we also performed an
analysis of the functions for all genes near DMRs.We joined each
high-grade or shared DMR to ENSEMBL genes within ±2 kb of
the DMR to predict functional impacts for DMRs that are near
genes. Our rationale for this definition is that even if total expres-
sion is not altered by DNA methylation, DNA methylation has
been shown to modulate alternative promoters (Maunakea
et al., 2010), alternative splicing (Shukla et al., 2011), and intronic
enhancers of the host gene (Agirre et al., 2015). We defined high-
grade genes (1,921 genes) as those that were associated with a
high-grade DMR and no shared DMRs and shared genes (4,820
genes) as any gene with a shared DMR (Figure 5A). We then
analyzed enrichment for Gene Ontology (GO) terms for the two
gene lists and identified common and unique GO terms (Table
S6; Figure 5B). The functions of the shared DMR genes containorts 13, 2135–2146, December 15, 2015 ª2015 The Authors 2141
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Figure 4. Correlation of DMR-overlapping TCGA Array Sites and Gene Expression from RNA-Seq
(A) Distribution of significant (FDR < 5%) correlation coefficients between TCGA sites that overlap with high-grade or shared DMRs and total gene expression
levels. ‘‘Promoter’’ (1,000 to +500 bp of a transcriptional start site for any isoform of the gene) and ‘‘gene body’’ assignments are made with respect to a
reference-guided de novo transcriptome assembly. The null expectation represents the distribution of correlation coefficients for each gene containing a
TCGA-assayed DMR with all sites on the array.
(B) High-grade DMR located in CCDC8. The normalized read counts (mean ± SEM) for each 50-bp window are plotted for each of the three sample groups. The
transcriptional start site annotated by the transcriptome assembly is given as an arrow. The locations of the correlating TCGA sites are denoted by orange lines.
(legend continued on next page)
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Table 1. Strong andSignificant Correlations between TCGASites
that Overlap with DMRs and Gene Expression
Promoter
(1,000 to +500
of a Putative
txStart)
Gene Body
(Non-promoter
Introns and
Exons)
High
Grade Shared
High
Grade Shared
DMR to TCGA Site Overlaps
Number of DMRs 505 1,626 3,575 5,657
DMRs with site on 450K 239 1,251 763 2,839
Sites on 450K with DMR 498 3,972 1,124 6,867
Sites on 450K with DMR and
IQR > 0.05
455 3,913 891 6,671
Total Expression Correlations (FDR < 5% and jrj > 0.4)
DMRs 8 74 33 175
Sites 13 232 46 406
Genes 9 75 26 147
IQR, interquartile range.nearly all the terms represented by the high-grade DMRs except
for 65 GO terms that were uniquely enriched in the high-grade
genes.
Network diagrams, where each connection between DMR-
proximal genes represents a curated interaction in a known
pathway, were constructed to visualize closely interacting genes
on these gene lists. Four functional categories of particular inter-
est to the aggressive cancer phenotype have been highlighted
(Figure 5C). The extracellular structure organization genes
interact and contain cytoskeletal components, and cytoskeletal
dysregulation is required for metastatic behavior of prostate
tumors (Cai et al., 2015). The unique enrichment and presence
of high-grade DMRs at RNA processing genes is intriguing, as
genome-wide changes in alternative splicing are observed
pan-cancer (Dvinge and Bradley, 2015), and the splicing factors
are potential therapeutic targets (Hsu et al., 2015). Finally, there
are 1,454 GO terms unique to the shared genes, and shared
genes are enriched for multiple pathways related to prostate
cancer including WNT signaling (Figure S4A). Using a graph-
theoretic approach, we determined that the high-grade and
shared gene sets are functionally distinct on an entire human
pathway network (Figure S4B). Also, the high-grade and shared
genes are strongly enriched for ‘‘hub’’ genes, which are highly
connected genes that may represent master regulators of a
given pathway or convergent points of multiple pathways (Fig-
ures S4C and S4D). Taken together, these results suggest that
DMRs identified in our study target functions pertinent for pros-
tate cancer biology, and more importantly, that the high-grade(C) Scatterplot of fractional methylation (beta-value) versus log2 CCDC8 express
(D) High-grade DMR located in HOXC4. Non-overlapping sites are given in black
(E) Scatterplot of fractional methylation (beta-value) versus log2 HOXC4 express
(F) Prostate cancer survival meta-analysis z-scores from PRECOG for genes that
the maximal jrj is shown in cases of multiple correlating sites per gene.
(G) High-grade DMR located in MYLK.
(H) Scatterplot of fractional methylation (beta-value) versus log2 MYLK expressio
Cell Repgenes are functionally distinct from the shared genes. In high-
grade cancers, DNA methylation may be mediating a distinct
set of primary, secondary, and higher-order influences on gene
regulation that lead to aggressiveness.
DISCUSSION
Our discovery of DMRs among benign prostatic tissue, low-
grade, and high-grade prostate cancers revealed pervasive,
focal hypermethylation events that are unique to aggressive dis-
ease. These DMRs are not restricted to the promoters of genes
and frequently occur in gene bodies and intergenic regions. Both
the high-grade and the shared DMRs contain a large proportion
of intergenic DMRs, and these are highly enriched for putative
protein binding as defined by ChIP-seq peaks and DNaseI
hypersensitive sites. For promoter and gene body DMRs, inte-
gration with RNA-seq data from TCGA revealed high-grade
DMRs with inverse correlations to gene expression for genes
where low expression associates with poor survival. Genes
near DMRs are enriched for positive regulation of cellular motility
and extracellular structure organization, which are both highly
relevant biological processes for aggressive disease. More
importantly, the high-grade DMRs target known aggressive-
ness-related genes and also reveal pathways that warrant further
investigation. By stratifying prostate cancer samples using Glea-
son score derived from radical prostatectomy, our DMRs relate
to biological criteria, as opposed to stratifications using recur-
rence that are influenced by stage of disease at presentation.
Thus, this work provides a global perspective on DNA methyl-
ation changes between indolent and aggressive prostate cancer,
answering urgent questions about the molecular differences
between these two types of disease.
TCGA provides a considerable resource for the molecular
characterization of many tumor types, including prostate cancer.
While our shared DMRs show very high concordance with TCGA
data, this rate is lower for the high-grade DMRs. However, only a
small subset of our high-grade DMRs overlaps with sites on
TCGA’s array. For those that do, variation in pathological grading
may provide a possible explanation for the differences in
observed patterns, as this inter-observer variability could affect
assignments between different Gleason grades and diminish
chances of observing statistical differences between the low-
and high-grade groups. While we have established high tumor
purity by histology in our cohort, extracted DNA may vary in
contribution from tumor and normal cells and thus may also
contribute to cross-cohort differences. Another possible expla-
nation for the discrepancy is the presence of hydroxymethylation
in low-grade samples that is detected as methylation by the
bisulfite-based methylation microarrays used by TCGA. Aber-
rations in TET2, an enzyme that converts 5-methylcytosine toion in FPKM for 537 TCGA samples.
.
ion in FPKM.
show significant correlations with DMR-overlapping TCGA sites. The site with
n in FPKM.
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A B
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Figure 5. Pathway Relationships among
Genes Associated with High-Grade DMRs
(A) Venn diagram showing the number of expressed
genes (FPKM > 0.5 in 10% or more of TCGA sam-
ples) derived from the high-grade DMRs and the
shared DMRs.
(B) Venn diagram showing the number of GO terms
derived from the high-grade DMR genes (1,921)
and the shared DMR genes (4,820).
(C) Network showing interactions in curated
pathway databases among all expressed genes
within ±2 kb of a high-grade DMR that do not also
contain shared DMRs. Gray nodes are query genes
near DMRs. Colored nodes represent genes near
DMRs that belong to statistically enriched GO term
categories as labeled. Nodes are sized propor-
tionally to their number of neighbors (degree).
Genes near DMRs that do not participate in in-
teractions based on the reference pathway data-
bases have been omitted. See also Figure S4A for
the shared DMR genes.5-hydroxymethylcytosine, have been suggested to play a role in
prostate cancer progression (Nickerson et al., 2013). If TET2
were downregulated in high-grade disease, the result could be
a gain of hypermethylation. Since the MiGS technique enriches
specifically for 5-methylcytosine, high-grade DMRs in our data-
set would appear as shared DMRs in the TCGA dataset, asmany
do (Figure 3B; Table S3). Adding to these factors is the single-
CpG nature of the microarray. Our DMRs are derived, both bio-
chemically and statistically, to represent regions of the genome
150 bp or larger. Comparison of this regional average to any sin-
gle CpG site in the given region will be prone to sampling error.
Shared DMRs are more common at CpG islands and CpG
shores than high-grade DMRs, which have been found to harbor
more stable methylation patterns based on meta-analysis on the
array platform (Edgar et al., 2014), and thusmay be less sensitive
to this error.2144 Cell Reports 13, 2135–2146, December 15, 2015 ª2015 The AuthorsPervasive focal hypermethylation was
found to be the most common and statis-
tically robust difference between indolent
and aggressive prostate cancer. These
DMRs spanned multiple genomic con-
texts, and the vast majority showed
enrichment for functional elements.
Expectedly, promoter methylation that re-
presses gene expression is detected, but
DMRs in gene bodies were found to have
both inverse and direct correlations with
gene expression. In addition, genes may
not necessarily show an expression
change despite the presence of a DMR,
and other hypotheses, such as alternative
splicing regulation (Shukla et al., 2011),
shared promoters with long noncoding
RNAs (Eun et al., 2013), and regional
enhancer effects (Sohni et al., 2015)
should be considered. For intergenic
DMRs, the enrichment of DNA-proteinbinding sites and motifs is suggestive of function, and the exact
nature will need to be defined by future molecular testing. In
particular, EZH2 binding sites were strongly enriched in inter-
genic regions. EZH2 overexpression is observed in castration-
resistant prostate cancer (Varambally et al., 2002) and is capable
of increasing aggressive phenotypes in prostate cancer cell lines
(Karanikolas et al., 2010). Furthermore, the intergenic DMRs
frequently reside in regions with enhancer characteristics. These
enrichment results strongly suggest that such regions are func-
tional and supports the view that disease-relevant DNA methyl-
ation can occur outside promoters. Future work will pursue the
specific roles of these DMRs in conferring the aggressiveness
phenotype and will reveal functions of DNA methylation in
different genomic contexts in the regulation of genes. Our com-
pendium of DMRs, which distinguish indolent from aggressive
prostate cancers, reveals the multiplicity of regulatory changes
in aggressive disease and renders a propitious set of regions for
future research that can lead to new diagnostic tools for clini-
cians and provide new approaches to targeting the pathways
epigenetically reshaped in aggressive prostate cancer.
EXPERIMENTAL PROCEDURES
Sample Collection and Pathological Grading
Formalin-fixed paraffin-embedded (FFPE) tissue samples were obtained from
radical cystoprostatectomies (benign prostates) and radical prostatectomies
(prostate cancers) performed at the Cleveland Clinic. All specimens were re-
viewed by a genitourinary pathologist (C.M.G.). We required no evidence of
tertiary high-grade patterns in low-grade specimens and required90%Glea-
son pattern 4/5 for high-grade specimens. Sequenced sections were taken
directly adjacent to slides used for pathological assessment. The collection
and use of the clinical specimens has been approved by the Cleveland Clinic
Institutional Review Board.
MBD-Isolated Genome Sequencing
Genomic DNA was extracted from FFPE samples and sequencing libraries
(average fragment length, 120 bp) were prepared following the protocol for
MiGS (Serre et al., 2010). Sequencing was performed to a read length of
36 bp (using the Illumina Genome Analyzer IIx) for some samples and 50 bp
for others (Illumina HiSeq 2000), due to platform changes. Downsampling
and trimming was performed to make the newer Illumina HiSeq 2000 runs
more comparable to the old (see Table S1 for details). The QC-passed
reads were aligned to hg19 using bowtie2 (Langmead and Salzberg, 2012).
A MAPQ cutoff of 10 was used. Duplicate reads were retained because
duplication rates were fairly consistent across samples and nearly always
below 30%.
Statistical Identification and Analysis of DMRs
We developed a computational approach for the statistical identification of
DMRs using MiGS data for replicated cohorts containing three groups. The
method consists of aggregating read counts from MiGS into 50 bp non-over-
lapping windows genome-wide, detecting statistically significant regions of
differences for all possible patterns between the groups, and then performing
bootstrapping to determine FDRs. We used ancestry group (European Amer-
ican or African American) as a covariate adjustment to control for this factor.
Statistical details of DMR detection, datasets and background sets used for
annotation, comparison to TCGA methylation arrays, processing of TCGA
RNA-seq data, and network analysis based on the DMRs are provided in Sup-
plemental Experimental Procedures. The software for DMR detection is avail-
able as an R package called ‘‘methylaction’’ at http://github.com/jeffbhasin/
methylaction. The genomic context of the DMRs were determined using our
R package ‘‘goldmine’’ (available at https://github.com/jeffbhasin/goldmine).
A visualization and data integration web application including all DMRs from
this study is available at http://dminer.lerner.ccf.org.
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